Aug. 18, 2021 Price forecast | 2 weeks: 2.50% | 1 month: 1.18% | 3 months: -8.15%


CERC stock forecast

Our latest prediction for Cerecor Inc's stock price was made on the Aug. 18, 2021 when the stock price was at 2.78$.

In the short term (2weeks), CERC's stock price should outperform the market by 2.50%. During that period the price should oscillate between -10.23% and +13.85%.

In the medium term (3months), CERC's stock price should underperform the market by -8.15%. During that period the price should oscillate between -47.14% and +31.80%.

Create a solid portfolio with CERC

Add CERC to your portfolio and optimize it!


About Cerecor Inc

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

At the moment the company generates 6M USD in revenues.

On its last earning announcement, the company reported a loss of -0.84$ per share.

The book value per share is 0.55$

Cerecor Inc website


Three months stock forecastAug. 18, 2021


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
6M 95.10% -77M -706.00% -77M -0.84 - - 84M 0.55 -64M - -64M